4.56
전일 마감가:
$4.82
열려 있는:
$4.85
하루 거래량:
28,631
Relative Volume:
0.27
시가총액:
$134.27M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.30%
1개월 성능:
+46.15%
6개월 성능:
+0.00%
1년 성능:
+0.00%
Turn Therapeutics Inc Stock (TTRX) Company Profile
명칭
Turn Therapeutics Inc
전화
(818) 564-4011
주소
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
TTRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
TTRX
Turn Therapeutics Inc
|
4.56 | 141.93M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-29 | 개시 | D. Boral Capital | Buy |
Turn Therapeutics Inc 주식(TTRX)의 최신 뉴스
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Turn Therapeutics advances atopic dermatitis trial, expands pipeline By Investing.com - Investing.com Nigeria
Speculative Buy on Turn Therapeutics: Proprietary Platform, Capital-Efficient Growth, and 2026 Milestones as Key Upside Catalysts - TipRanks
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Turn Therapeutics advances atopic dermatitis trial, expands pipeline - Investing.com
Turn Therapeutics Issues Corporate, Pipeline and Financial Updates - TipRanks
Turn Therapeutics Inc Announces Corporate and Pipeline Updates for 2026 - TradingView — Track All Markets
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44 - Business Wire
TTRX Forecast — Price Target — Prediction for 2027 - TradingView — Track All Markets
Turn Therapeutics Reaches US$132m Market Cap Benefiting Insider Stock Buying - Sahm
Will Stoke Therapeutics Inc. stock split again soonVolume Spike & Technical Buy Zone Confirmations - ulpravda.ru
Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they haven’t stopped buying - Yahoo Finance
Turn Therapeutics adds McKinsey veteran to board amid M&A focus By Investing.com - Investing.com Nigeria
Los Angeles Daily NewsTurn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Turn Therapeutics appoints Martin Dewhurst to its board of directors - marketscreener.com
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors - TradingView — Track All Markets
Turn Therapeutics appoints veteran executive to board - TipRanks
Turn Therapeutics adds McKinsey veteran to board amid M&A focus - Investing.com
Turn Therapeutics Inc. Appoints Martin Dewhurst to Board of Directors - TradingView — Track All Markets
Turn Therapeutics (TTRX) Stock Analysis Report | Financials & Insights - Benzinga
Ceapro (OTCMKTS:CRPOF) vs. Turn Therapeutics (NASDAQ:TTRX) Head to Head Review - Defense World
Turn Therapeutics (NASDAQ:TTRX) Upgraded at D Boral Capital - Defense World
Turn Therapeutics (NASDAQ:TTRX) Now Covered by Analysts at D. Boral Capital - Defense World
TTRX Analyst Forecasts - Quiver Quantitative
Turn Therapeutics Inc. Common Stock (TTRX) Stock News & Articles - 24/7 Wall St.
D. Boral Capital initiates Turn Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
What date does Turn Therapeutics Inc.'s (TTRX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Death Cross: Is Beam Therapeutics Inc. stock a defensive play in 2025Exit Point & Safe Entry Zone Identification - moha.gov.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Will Tempest Therapeutics Inc. stock beat EPS estimatesJuly 2025 Weekly Recap & Weekly High Potential Stock Alerts - bolumsonucanavari.com
Portfolio Shifts: Is Enliven Therapeutics Inc. stock near bottom after decline2025 Volatility Report & Daily Entry Point Trade Alerts - moha.gov.vn
Will Whitehawk Therapeutics Inc. stock recover faster than market2025 Earnings Surprises & Detailed Earnings Play Alerts - Улправда
Can Karyopharm Therapeutics Inc. stock resist sector downturnsJuly 2025 Market Mood & High Accuracy Trade Alerts - Улправда
Why MiNK Therapeutics Inc. stock attracts global investors2025 Market Trends & Short-Term High Return Ideas - Улправда
Is Foghorn Therapeutics Inc. stock resilient to inflation2025 Support & Resistance & Real-Time Chart Breakout Alerts - Улправда
Why Anika Therapeutics Inc. stock remains on watchlistsMarket Activity Report & Community Trade Idea Sharing - Улправда
Will Neumora Therapeutics Inc. stock benefit from AI adoptionOil Prices & Weekly Setup with High ROI Potential - Улправда
Loss Report: Can Xilio Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 EndofMonth & High Win Rate Trade Alerts - Улправда
Will Intensity Therapeutics Inc. stock split attract more investorsJuly 2025 News Drivers & AI Based Buy and Sell Signals - Улправда
How geopolitical tensions affect Spyre Therapeutics Inc. stock2025 Historical Comparison & Real-Time Volume Trigger Notifications - ulpravda.ru
Is Cidara Therapeutics Inc. stock a top momentum playMarket Activity Report & AI Enhanced Trade Execution Alerts - Улправда
Is Beam Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Report & Short-Term High Return Strategies - Улправда
Is Aquestive Therapeutics Inc. stock positioned for digital transformation2025 Key Highlights & Expert Approved Trade Ideas - Улправда
Will Tempest Therapeutics Inc. stock split again soonJuly 2025 Earnings & Accurate Intraday Trading Signals - Улправда
How Marker Therapeutics Inc. (GX1) stock reacts to new regulationsJuly 2025 Earnings & Low Volatility Stock Recommendations - Улправда
Will TG Therapeutics Inc. stock benefit from automationMarket Activity Report & Free Expert Verified Stock Movement Alerts - Улправда
Turn Therapeutics Inc. (TTRX) - Zacks Investment Research
CFO Chaudhary Buys 2,500 ($8.8K) Of Turn Therapeutics Inc [TTRX] - TradingView — Track All Markets
Can Black Diamond Therapeutics (BDTX) Turn Silevertinib’s Dual-Cancer Ambition Into a Cohesive Strategy? - Yahoo Finance
Is CytomX Therapeutics Inc. (6C1) stock attractive for dividend growthJuly 2025 Snapshot & Technical Pattern Based Buy Signals - moha.gov.vn
Why Intensity Therapeutics Inc. stock appeals to analystsQuarterly Portfolio Review & Free Risk Controlled Daily Trade Plans - moha.gov.vn
Turn Therapeutics Inc (TTRX) 재무 분석
Turn Therapeutics Inc (TTRX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Turn Therapeutics Inc 주식 (TTRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GOLDEN ARTHUR F | Director |
Nov 24 '25 |
Buy |
3.44 |
9,868 |
33,946 |
60,602 |
| GOLDEN ARTHUR F | Director |
Nov 21 '25 |
Buy |
2.87 |
20,532 |
58,927 |
50,734 |
| Chaudhary Zuraiz | See Remarks |
Nov 20 '25 |
Buy |
2.61 |
1,450 |
3,784 |
9,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 21 '25 |
Buy |
3.29 |
1,000 |
3,290 |
10,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 17 '25 |
Buy |
3.62 |
2,500 |
9,050 |
7,550 |
| Chesed Abraham | Board Observer |
Oct 23 '25 |
Buy |
4.60 |
14,286 |
65,716 |
1,447,268 |
| Chaudhary Zuraiz | See Remarks |
Oct 23 '25 |
Buy |
4.95 |
5,050 |
24,998 |
5,050 |
| GOLDEN ARTHUR F | Director |
Oct 23 '25 |
Buy |
4.95 |
20,202 |
100,000 |
30,202 |
자본화:
|
볼륨(24시간):